Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2009-12-07 Director's Dealing
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act, which relate to disclosures of directors' personal share transactions. The content details a director's sale of shares, including dates, quantities, and prices. There is no financial performance data, report, or meeting information. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is about 6,050 characters, sufficient for a detailed notice but not a full report. Therefore, the correct classification is DIRS with high confidence.
2009-12-07 English
Change in substantial holding 4 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001. It details changes in voting power and relevant interests of a substantial shareholder in Pharmaxis Ltd. This type of filing is a notification of changes in significant share ownership levels, which corresponds to a Major Shareholding Notification. The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2009-12-02 English
PHARMAXIS ANNOUNCES SUSTAINED BENEFIT WITH BRONCHITOL 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release announcing the results of a Phase III clinical trial for a pharmaceutical product (Bronchitol) by Pharmaxis. It contains detailed clinical trial results, safety data, and forward-looking statements but does not include financial statements, regulatory filings, or formal report structures. It is not an earnings release, annual report, or regulatory filing. The content is a public announcement of clinical trial outcomes rather than a financial or governance report. Therefore, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2009-12-01 English
Appendix 3B - Exercise of Employee Options 10 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) announcement used to notify the market of a new issue of securities, application for quotation of additional securities, or agreement related to securities. It details the class and number of securities issued, issue price, purpose of the issue, and other related information. This type of document is specifically related to capital raising or changes in capital structure, such as issuing new shares or options. It is not a financial report, earnings release, or management discussion, but rather a formal announcement of a capital/financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the securities issued, confirming it is not merely a brief announcement or a report publication notice.
2009-11-25 English
Change of Director`s Interest Notice - Appendix 3Y 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the exercise of options and acquisition of shares. The content is focused on insider share transactions by a company director. The document length is 3208 characters, which is consistent with a detailed notice of director dealings rather than a brief announcement or a full report. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades).
2009-11-25 English
FDA Advisory Committee Recommends Approval of Aridol 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 23 November 2009 from Pharmaxis Ltd announcing that an FDA advisory committee has recommended approval of their product Aridol. It discusses the FDA advisory committee's votes, the product's clinical trial data, and the regulatory process including the NDA filing and expected FDA decision date. The document is a public announcement of a regulatory event related to product approval, not a financial report, earnings release, or detailed investor presentation. It does not contain financial statements or detailed financial analysis. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory advisory committee recommendation. The content fits best under a Regulatory Filings (RNS) category as a general regulatory announcement about FDA advisory committee recommendation and regulatory progress.
2009-11-22 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.